Alnylam Pharmaceuticals in the news

Alnylam is investing $250 million to expand its Massachusetts facility with an FDA-accepted enzymatic ligation platform to boost RNAi therapeutic manufacturing capacity and reduce costs.

Alnylam Pharmaceuticals is transitioning to a commercial-scale biotech with strong revenue growth from Amvuttra, Nasdaq-100 inclusion, UK reimbursement approval, manufacturing expansion, and ongoing federal scrutiny.

Alnylam Pharmaceuticals saw notable insider and institutional stock sales amid generally positive analyst ratings, continuing its focus on RNAi therapeutics development.

Alnylam Pharmaceuticals saw a strong stock surge and 103% revenue growth in Q3 2025, driven by a successful Amvuttra launch.

Alnylam is investing $250 million to expand its Massachusetts facility to boost siRNA therapeutic manufacturing capacity and reduce costs.

Alnylam is investing $250 million to expand its Norton facility for scalable, sustainable RNAi therapeutic manufacturing using its siRELIS platform, aiming to support future drug launches by 2027.

Alnylam is investing $250M to consolidate manufacturing from 20 plants to 2 as it expands into common disease treatments.

Alnylam is spending $250M to enhance its Massachusetts facility with siRELIS enzymatic ligation tech to boost RNAi drug production capacity and efficiency, supporting pipeline expansion.

Alnylam is investing $250 million to expand its Massachusetts facility with a new enzymatic ligation platform to boost RNAi therapeutic production capacity and reduce costs, supporting future drug launches.

Alnylam Pharmaceuticals shows a near-term breakout with strong positive sentiment, neutral mid-term outlook, and long-term positive bias amid some downside risk.

Alnylam Pharmaceuticals' stock has surged over 100% this year due to strong financing, pipeline progress, and partnerships, though its valuation slightly exceeds fair value amid growth and margin risks.

The article analyzes options market activity suggesting investors may expect a rise in Alnylam Pharmaceuticals' stock price.

Alnylam Pharmaceuticals shows strong momentum with significant stock gains and favorable rankings, outperforming its industry and the market.

Alnylam Pharmaceuticals stock hit a record high driven by strong drug sales, positive clinical results, and favorable analyst outlooks.

Alnylam Pharmaceuticals' stock narrative is improving due to strong commercial results and promising clinical data, though some analysts remain cautious about valuation and pipeline risks.

Alnylam Pharmaceuticals has outperformed its Medical sector peers this year with a 97.6% return and improved earnings outlook.

Alnylam Pharmaceuticals stock is forming a flat base with strong technical indicators and a 100% gain this year, offering a new entry point.

Alnylam Pharmaceuticals has launched a Phase 3 trial for zilebesiran in cardiovascular disease, aiming to diversify its RNAi therapy portfolio beyond rare diseases while current growth relies on AMVUTTRA.

Alnylam Pharmaceuticals, focused on RNAi therapeutics, shows strong stock momentum with multiple FDA-approved drugs and significant recent price gains.

Alnylam Pharmaceuticals is a leading RNAi biotech with a strong pipeline, positive cash flow, strategic partnerships, and mixed analyst sentiment on its stock.